Curon is a clinical stage biopharmaceutical company dedicated to developing and commercializing the next generation cancer therapies. The company is currently focusing on immuno-oncology and targeted therapies to address unmet medical needs and provide effective treatment options for cancer patients all over the world.
Since its inception in 2018, Curon has established a seasoned executive team with extensive experience in drug discovery, translational research, pre-clinical and clinical development. The company has built a pipeline of 6 innovative drug candidates through internal discovery and external collaboration.
With the experienced team, and strong financial support from prestigious investors, Curon strives to become a reputable biopharmaceutical company in providing patients with effective treatment options worldwide.
